Skip to main content

Advertisement

SpringerLink
Log in

Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors

  • Clinical Study - Patient Studies
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Seizures are a common complication of metastatic brain tumors (MBT), affecting approximately 27–50% of all patients during the course of their illness. Treatment of tumor-induced seizures is often inadequate with traditional antiepileptic drugs (AED) due to a variety of factors, including activation of glutamatergic NMDA receptors, alterations of neuronal input pathways, and tumor growth. Levetiracetam (LEV) is a 2nd generation non-enzyme inducing AED with a novel mechanism of action, binding to neuronal synaptic vesicle protein SV2A, that has been previously shown to reduce seizure activity in patients with primary brain tumors. Due to its unique mechanism of action, it has been postulated that LEV may also be effective in controlling seizures from MBT. A retrospective chart review was performed of all Neuro-Oncology Center patients with MBT who had received LEV for seizure control. Thirteen patients were reviewed with a median age of 55.1 years (range: 34–70). Six patients had breast cancer, five had lung cancer, and two had melanoma. LEV was used as an add-on AED in seven patients (54%) and as monotherapy in six patients (46%), with a median dose of 1,000 mg/day (range: 500–3,000). The baseline median seizure frequency was one ictal event every other day. After the addition of LEV, the median seizure frequency was reduced to 0 per week. The seizure frequency was reduced to less than 50% of the pre-LEV baseline in 100% of patients (P = 0.0002, Sign test), with 10 patients (77%; confidence interval: 46–95%) noting complete seizure control. The most common adverse event was somnolence and headache, noted in 3 of 13 patients (23%). LEV was very effective and well tolerated in MBT patients with seizures and should be considered for add-on therapy or as a substitute AED for monotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Arnold SM, Patchell RA (2001) Diagnosis and management of brain metastases. Hematol Oncol Clin North Am 15:1085–1107

    Article  PubMed  CAS  Google Scholar 

  2. Posner JB, Chernik NL (1978) Intracranial metastases from systemic cancer. Adv Neurol 19:579–592

    PubMed  CAS  Google Scholar 

  3. Soffietti R, Ruda R, Mutani R (2002) Management of brain metastases. J Neurol 249:1357–1369

    Article  PubMed  Google Scholar 

  4. Oberndorfer S, Schmal T, Lahrmann H et al (2002) The frequency of seizures in patients with primary brain tumors or cerebral metastases. An evaluation from the Ludwig Boltzmann Institute of Neuro-Oncology and the Department of Neurology, Kaiser Franz Josef Hospital, Vienna. Wien Klin Wochenschr 114:911–916

    PubMed  Google Scholar 

  5. Schaller B, Ruegg SJ (2003) Brain tumor and seizures: pathophysiology and its implications for treatment revisited. Epilepsia 44:1223–1232

    Article  PubMed  Google Scholar 

  6. Glantz MJ, Cole BF, Forsyth PA et al (2000) Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors-report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurol 54:1886–1893

    CAS  Google Scholar 

  7. El Kamar FG, Posner JB (2004) Brain metastases. Semin Neurol 24:347–362

    Article  PubMed  Google Scholar 

  8. Fetell MR, Grossman SA, Fisher JD et al (1997) Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New approaches to Brain Tumor Therapy Central Nervous System Consortium. J Clin Oncol 15:3121–3128

    PubMed  CAS  Google Scholar 

  9. Liddle C, Goodwin BJ, George J et al (1998) Separate and interactive regulation of cytochrome P450 3A4 by triidothyronine, dexamethasone, and growth hormone in cultured hepatocytes. J Clin Endocrinol Metab 83:2411–2416

    Article  PubMed  CAS  Google Scholar 

  10. Patsalos PN (2000) Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 85:77–85

    Article  PubMed  CAS  Google Scholar 

  11. Stevens GH (2005) Antiepileptic drug use in patients with brain tumors. Profiles in Seizure Manage 4:5–9

    Google Scholar 

  12. Stahl SM (2004) Psychopharmacology of anticonvulsants: levetiracetam as a synaptic vesicle protein modulator. J Clin Psychiatry 65:1162–1163

    Article  PubMed  Google Scholar 

  13. Lynch BA, Lambeng N, Nocka K et al (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 101:9861–9866

    Article  PubMed  CAS  Google Scholar 

  14. Niespodziany I, Klitgaard H, Margineanu DG (2000) Levetiracetam: modulation of high voltage activated C++ current in CA1 pyramidal neurons of rat hippocampal slices (abstract). Epilepsia 41:37

    Article  Google Scholar 

  15. Lukyanetz EA, Shkryl VM, Kostyuk PG (2002) Selective blockade of n-type calcium channels by levetiracetam. Epilepsia 43:9–18

    Article  PubMed  CAS  Google Scholar 

  16. Rigo JM, Hans G, Nguyen L et al (2002) The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol 136:59–672

    Article  Google Scholar 

  17. Cardile V, Pavone A, Gulino R et al (2003) Expression of brain-derived neurotrophic factor (BDNF) and inducible nitric oxide synthase (iNOS) in rat astrocyte cultures treated with levetiracetam. Brain Res 976:227–233

    Article  PubMed  CAS  Google Scholar 

  18. Hanon E, Klitgaard H (2001) Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia. Seizure 10:287–293

    Article  PubMed  CAS  Google Scholar 

  19. Wagner GL, Wilms EB, Van Donselaar GA et al (2003) Levetiracetam: preliminary experience in patients with primary brain tumours. Seizure 12:585–586

    Article  PubMed  CAS  Google Scholar 

  20. Newton HB, Goldlust SA, Pearl D (2006) Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. J Neurooncol 78:157–160

    Article  PubMed  Google Scholar 

  21. Maschio M, Albani F, Baruzzi A et al (2006) Levetiracetam therapy in patients with brain tumour and epilepsy. J Neurooncol 80:97–100

    Article  PubMed  CAS  Google Scholar 

  22. Alsaadi TM, Shatzel A, Marquez AV et al (2005) Clinical experience of levetiracetam monotherapy for adults with epilepsy: 1-year follow-up study. Seizure 14:139–142

    Article  PubMed  Google Scholar 

  23. Labate A, Colosimo E, Gambardella A et al (2006) Levetiracetam in patients with generalised epilepsy and myoclonic seizures: an open label study. Seizure 15:214–218

    Article  PubMed  Google Scholar 

  24. Brodie MJ, Perucca E, Ryvlin P et al (2007) Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurol 68:402–408

    Article  CAS  Google Scholar 

  25. French JA, Kanner AM, Bautista J et al (2004a) Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy. Neurol 62:1252–1260

    CAS  Google Scholar 

  26. French JA, Kanner AM, Bautista J et al (2004b) Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy. Neurol 62:1261–1273

    CAS  Google Scholar 

  27. Payakachat N, Summers KH, Barbuto JP (2006) A comparison of clinical practice guidelines in the initial pharmacological management of new-onset epilepsy in adults. J Manag Care Pharm 12:55–60

    PubMed  Google Scholar 

  28. Glantz M, Recht LD (1997) Epilepsy in the cancer patient. In: Vecht CJ (ed) Handbook of Clinical Neurology. Elsevier Science, Amsterdam, pp 9–18

    Google Scholar 

  29. Kivisto KT, Kroemer HK, Eichelbaum M (1995) The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 40:523–530

    PubMed  CAS  Google Scholar 

  30. Vecht CJ, Wagner GL, Wilms EB (2003a) Treating seizures in patients with brain tumors: drug interactions between antiepileptic and chemotherapeutic agents. Semin Oncol 30:49–52

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dardinger Neuro-Oncology Center and Division of Neuro-Oncology, Department of Neurology, Ohio State University Medical Center, Columbus, OH, USA

    Herbert B. Newton, Jennifer Dalton & Samuel Goldlust

  2. Ohio State University School of Medicine and Public Health, Columbus, OH, USA

    Jennifer Dalton & Samuel Goldlust

  3. Department of Statistics, Ohio State University Medical Center and James Cancer Hospital & Solove Research Institute, Columbus, OH, USA

    Dennis Pearl

Authors
  1. Herbert B. Newton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jennifer Dalton
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Samuel Goldlust
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dennis Pearl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Herbert B. Newton.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Newton, H.B., Dalton, J., Goldlust, S. et al. Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors. J Neurooncol 84, 293–296 (2007). https://doi.org/10.1007/s11060-007-9373-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-007-9373-8

Keywords

Search

Navigation